Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at Zacks Research

Posted by Stanley Muller on Jun 25th, 2026

Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was upgraded by Zacks Research to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

MCRB has been the topic of several other research reports. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a research note on Friday, March 13th. HC Wainwright initiated coverage on shares of Seres Therapeutics in a report on Tuesday. They issued a “buy” rating and a $12.00 price target for the company. Finally, Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.00.

Check Out Our Latest Research Report on MCRB

Seres Therapeutics Stock Down 3.2%

Shares of NASDAQ:MCRB opened at $6.83 on Tuesday. The business has a 50 day moving average price of $7.43 and a 200 day moving average price of $10.59. Seres Therapeutics has a twelve month low of $5.31 and a twelve month high of $29.98. The company has a market cap of $66.07 million, a price-to-earnings ratio of -1.32 and a beta of 0.13.

Seres Therapeutics (NASDAQ:MCRB – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The business had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million. Analysts anticipate that Seres Therapeutics will post -5.84 EPS for the current year.

Institutional Trading of Seres Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 21,679 shares during the period. Invesco Ltd. grew its stake in shares of Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 89,995 shares during the period. Bank of America Corp DE raised its holdings in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares in the last quarter. Barclays PLC raised its holdings in shares of Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after buying an additional 6,024 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $190,000. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

(Get Free Report)

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.